Medivation's (NASDAQ:MDVN) talazoparib has breast cancer experts closely watching whether the drug's high potency will set it back in the chemo-combination space.
Talazoparib's potency differentiates it from other PARP inhibitors in BRCA mutated metastatic breast cancer, experts agreed. But that could also affect its potential for a combination approach, which other PARP inhibitors are working toward, said several experts. Coupling a PARP inhibitor with a chemotherapy in metastatic breast cancer could expand the patient population, experts noted.
While experts emphasized that there hasn't been definitive clinical data to hamper talazoparib's combination chances, they suggested that if the high potency impacts its side-effect profile, a chemotherapy combination could increase bone marrow toxicities.
As a single agent, experts found talazoparib offers a significant advantage over standard chemotherapies and has less negative effects on quality of life. The Phase III EMBRACA trial (NCT01945775) of talazoparib monotherapy is expected to finish accrual in 2016 and read out in 1H17, said a Medivation spokesperson.